← All trials
NCT05431179
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2022
- Primary completion
- Nov 30, 2026
- Completion date
- Dec 31, 2026
- First posted
- Jun 24, 2022
- Last posted
- Jun 24, 2022
- Enrollment
- 365
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Oncternal TherapeuticsLead sponsor
- PharmacyclicsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.